Gadoterate (Dotarem/Clariscan) — Competitive Intelligence Brief

Gadoterate (Dotarem/Clariscan) (Gadoterate (Dotarem/Clariscan)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gadolinium-based contrast agent. Area: Diagnostic Imaging.

marketed Gadolinium-based contrast agent Water protons (via paramagnetic gadolinium ion) Diagnostic Imaging Small molecule

Target snapshot

Gadoterate (Dotarem/Clariscan) (Gadoterate (Dotarem/Clariscan)) — Bayer. Gadoterate is a gadolinium-based contrast agent that accumulates in tissues and enhances MRI signal to improve visualization of anatomical structures and lesions.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gadoterate (Dotarem/Clariscan) TARGET	Gadoterate (Dotarem/Clariscan)	Bayer	marketed	Gadolinium-based contrast agent	Water protons (via paramagnetic gadolinium ion)
Gadavist	GADOBUTROL	Bayer	marketed	Gadolinium-based Contrast Agent [EPC]		2011-01-01
Dotarem®-enhanced MRI	Dotarem®-enhanced MRI	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)
Gadopentetate-Dimeglumine 0.05 mmol	Gadopentetate-Dimeglumine 0.05 mmol	Paracelsus Medical University	marketed	Gadolinium-based contrast agent	Water protons (T1 relaxation enhancement)
Gadopentetate-Dimeglumine 0.0125 mmol	Gadopentetate-Dimeglumine 0.0125 mmol	Paracelsus Medical University	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)
DOTAREM	DOTAREM	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 and T2 relaxation times)
Gadovist®/Gadavist®	Gadovist®/Gadavist®	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gadolinium-based contrast agent class)

1. Guerbet · 4 drugs in this class
2. Bayer · 4 drugs in this class
3. Paracelsus Medical University · 2 drugs in this class
4. GE Healthcare · 1 drug in this class
5. Bracco Diagnostics, Inc · 1 drug in this class
6. Seoul National University Hospital · 1 drug in this class
7. Shanghai Shengdi Pharmaceutical Co., Ltd · 1 drug in this class
8. The Central Hospital of Lishui City · 1 drug in this class